Showing results (441-450 of 549) with videos related to

Sort By:
Pageof 55
The Journal of Pharmacology and Experimental Therapeutics|February 1, 2025
Therapeutic targeting of full-length interleukin-33 protein levels with cell-permeable decoy peptides attenuates fibrosis in the bleomycin model in vivoSergei P Atamas, Virginia Lockatell, Nevins W Todd, et al.
Alcohol, Clinical & Experimental Research|July 12, 2023
Effects of adolescent ethanol exposure on adult nondrug reward seeking behavior in male and female miceLaura L Giacometti, Christine M Side, Kelsey Chandran, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 17, 1999
Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: a phase II study conducted by the Hellenic Cooperative Oncology GroupG Fountzilas, G Stathopoulos, C Nicolaides, et al.
Molecular Oncology|January 20, 2026
Correlation of the differential expression of PIK3R1 and its spliced variant, p55α, in pan-cancerIshita Gupta, Yang Song, Madeleine Ndahayo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 26, 2005
The outcome of elderly patients with advanced urothelial carcinoma after platinum-based combination chemotherapyA Bamias, E Efstathiou, L A Moulopoulos, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 24, 1999
Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II studyN Androulakis, C Kourousis, M A Dimopoulos, et al.
Transplantation|July 17, 2001
Pancreas transplantation: the histologic morphology of graft loss and clinical correlationsC B Drachenberg, J C Papadimitriou, A Farney, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 29, 2012
Full-length IL-33 promotes inflammation but not Th2 response in vivo in an ST2-independent fashionIrina G Luzina, Edward M Pickering, Pavel Kopach, et al.
Pageof 55